Page 2 - ஆய்வகம் வரையறுக்கப்பட்டவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Zai Lab Announces First Patient Treated in China in the

Zai Lab Announces First Patient Treated in China in the Registrational Phase 2 TRIDENT-1 Study of Repotrectinib May 28, 2021 07:30 ET | Source: Zai Lab Limited Zai Lab Limited TRIDENT-1 study is enrolling patients with ROS1+ advanced NSCLC and NTRK+ advanced solid tumors. SHANGHAI and SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company today announced dosing of the first patient in China in the registrational Phase 2 portion of TRIDENT-1 study of repotrectinib being conducted by its partner Turning Point Therapeutics, Inc. and Zai Lab in patients with ROS1+ advanced non-small cell lung cancer (NSCLC) and NTRK+ advanced solid tumors. Zai Lab has an exclusive license agreement with Turning Point for the development and commercialization of repotrectinib in Greater China (mainland China, Hong Kong, Macau, and Taiwan).

Hong kongAlan sandlerPoint therapeutics incOncology of zai labZai labWorld health organizationDrug administrationHead of global developmentZai lab limitedLab limitedTurning point therapeuticsTurning pointGreater chinaGlobal developmentBlinded independent central reviewNon small cell lung cancer

StreetInsider com - Corporate News

StreetInsider com - Corporate News
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Top of mind networks forAmblack knight incAmkulicke soffa industriesCommon stock in exchangeAmlyondellbasell industriesAmzai lab limitedSoffa industriesAnnounces agreementsCommon stockSenior convertible debenturesAcquire topMind networksLab limitedReports first patient treatedRegistrational phaseRevenues beat

argenx Reports First Quarter 2021 Financial Results and

1 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today reported financial results for the first quarter 2021 and provided a business update. “We’ve had a strong start to 2021 with the acceptance for review of the BLA and J-MAA for efgartigimod in gMG by the regulatory agencies in the U.S. and Japan. The submissions in China and the EU are on track and we are well-positioned for a global launch of our first-in-class FcRn antagonist. We are building an exceptional team with significant launch experience in neurology and rare disease and hope to reach patients this year,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

Van hauwermeirenTim van hauwermeirenZai labDrug administrationNational medical products administrationDevice agencyEuropean medicines agencyJapan pharmaceuticalsImmunology innovation programCilag gmbh internationalJapanese marketing authorization applicationMedical device agencyChief executive officerLicense applicationPrescription drug user fee actLab limited

5 Best Pharmaceutical Stocks to Buy According to Billionaire Kerr Neilson

5 Best Pharmaceutical Stocks to Buy According to Billionaire Kerr Neilson Neilson’s Stake Value: $7,262,000 Percent of Kerr Neilson’s 13F Portfolio: 0.16% Number of Hedge Fund Holders: 30 Zai Lab Limited (NASDAQ: ZLAB) is a Chinese biopharmaceutical company that specialises in discovering, developing, licencing, and commercializing therapeutics for treatment of oncology, autoimmune, and infectious diseases. Early this year, the company announced its financial results for the second half and full year of 2020 in which it reported $49.0 million in total revenues for the FY 2020 compared to $13.0 million reported in the FY 2019. During the year, biopharmaceutical company’s sales of Optune amounted to $16.4 million compared to $6.4 million reported in the previous year. Zai Lab reported a net loss of $268.9 million or $3.46 per share in FY2020 compared to a net loss of $195.1 million or $3.03 per share reported in FY2019.

Hong kongKerr neilsonPoint therapeutics incZai labNumber of hedge fund holdersZai lab limitedPharmaceutical stocksBuy accordingBillionaire kerrLab limitedStake valueHedge fund holdersTurning point therapeuticsTurning pointஹாங் காங்கெர் நீல்சன்

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABCL) - The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABCL) - The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

United statesStrongbridge biopharmaCellular therapies incMatinas biopharma holdings incCyclacel pharmaceuticals incCastle biosciences incOpiant pharmaceuticals incBiotechnology corporationInovio pharmaceuticals incAmicus therapeutics incSio gene therapies incHalozyme therapeutics incAthenex incFate therapeutics incPfizer incLyra therapeutics inc